Brazil antitrust regulator, known as CADE, unanimously approved in a session broadcast online the purchase by Hypera of Buscopan drug line from Boehringer Ingelheim GmbH for 1.3 billion reais (US$252.5 million), reported Bloomberg.
Deal was approved on condition that Hypera divests from the products that compete with Buscopan.
Hypera, since the beginning of the operation, presented a proposal to sell its medicine Neocopan Composto to the company Uniao Quimica Farmaceutica Nacional to guarantee the approval of the deal.
Sale of Neocopan Composto has been carried out and approved by CADE previously.
Full Content: Bloomberg
Want more news? Subscribe to CPI’s free daily newsletter for more headlines and updates on antitrust developments around the world.
Featured News
Plaintiffs Seek Communications In Antitrust Case Against Pioneer
May 9, 2024 by
CPI
UK Government Approves Vodafone-Hutchison Merger
May 9, 2024 by
CPI
Senate Majority Leader Announces Plan for AI Regulation Framework
May 9, 2024 by
CPI
BBVA Initiates Aggressive Takeover Bid for Sabadell
May 9, 2024 by
CPI
TikTok to Label AI-Generated Content Amid Election Interference Concerns
May 9, 2024 by
CPI
Antitrust Mix by CPI
Antitrust Chronicle® – Ecosystems
May 9, 2024 by
CPI
Mapping Antitrust onto Digital Ecosystems
May 9, 2024 by
CPI
Ecosystems and Competition Law: A Law and Political Economy Approach
May 9, 2024 by
CPI
Ecosystem Theories of Harm: What is Beyond the Buzzword?
May 9, 2024 by
CPI
Open Ecosystems: Benefits, Challenges, and Implications for Antitrust
May 9, 2024 by
CPI